Home » Topics » Regulatory » EMA

EMA
RSS

EMA issues positive opinion on Atara Biotherapeutics' CMVpp65-CTL

Oct. 13, 2016

EMA grants orphan drug designation to Videregen's replacement trachea product

Oct. 7, 2016

EMA grants SME designation to Dipexium Pharmaceuticals

Oct. 5, 2016

EMA accepts for review MAA for Herceptin biosimilar SB-3

Oct. 4, 2016

EMA accepts and validates masitinib MAA for ALS

Oct. 3, 2016

FDA grants orphan drug designation to BIIB-067 for the treatment of ALS

Sep. 26, 2016

EMA premature in notification of SomaKit TOC opinion

Sep. 23, 2016

EMA grants PRIME scheme access to Bluebird's Lentiglobin and Juno's JCAR-015

Sep. 22, 2016

AstraZeneca withdraws MAA for cediranib

Sep. 22, 2016

EMA validates BMS' application to extend Opdivo indications

Sep. 21, 2016

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...